Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer

[1]  M. Piccart-Gebhart,et al.  Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. , 2012, European journal of cancer.

[2]  G. Wilding,et al.  Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Saad,et al.  Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Amadori,et al.  Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA) , 2011 .

[5]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[6]  F. Saad,et al.  Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Smith,et al.  Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Amadori,et al.  Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models , 2009, Journal of cellular and molecular medicine.

[9]  M. Galsky,et al.  Docetaxel-based combination therapy for castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Carducci,et al.  Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[12]  D. Amadori,et al.  In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. , 2010, Current cancer drug targets.

[13]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[14]  P. Kantoff,et al.  A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Larry Rubinstein,et al.  Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee , 2010, Clinical Cancer Research.

[16]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[17]  G. Adluru,et al.  Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). , 2009, Journal of Clinical Oncology.

[18]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[19]  J. Verweij.  'No risk, no fun': challenges for the oncology phase I clinical trial time-performance. , 2008, European journal of cancer.

[20]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[21]  L. Collette.  Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, European urology.

[22]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[23]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Ryan,et al.  Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancer , 2008, Cancer.

[25]  S. Steinberg,et al.  A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[26]  L. Seymour,et al.  A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Hidalgo,et al.  A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Unger,et al.  Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. , 2007, European journal of cancer.

[31]  D. Strumberg,et al.  Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Radtke,et al.  Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.

[33]  K. Flaherty,et al.  Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma , 2005 .

[34]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[36]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[37]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[38]  J. Verweij,et al.  Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel , 2004, Clinical pharmacology and therapeutics.

[39]  J. Baranda,et al.  Docetaxel and ketoconazole in advanced hormone‐refractory prostate carcinoma , 2003, Cancer.

[40]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[42]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[43]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Picus,et al.  Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. , 1999, Seminars in oncology.

[45]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[46]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[47]  G. Montay,et al.  Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. , 1992, Journal of chromatography.